Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12;14(14):2850.
doi: 10.3390/nu14142850.

Association of Albumin and Globulin with Mortality Risk in Incident Peritoneal Dialysis Patients

Affiliations

Association of Albumin and Globulin with Mortality Risk in Incident Peritoneal Dialysis Patients

Kuan-Ju Lai et al. Nutrients. .

Abstract

Background: Nutrition and inflammation have been implicated in predicting mortality in patients on peritoneal dialysis (PD). Serum albumin and globulin can be regarded for the nutritional and inflammatory status. However, there is lack of data to evaluate the synergistic effect of albumin and globulin on mortality prediction. Methods: In 554 patients initiating PD from January 2001 to July 2016, we divided them into four groups by the combination of two categories of low vs. high albumin and low vs. high globulin. The median values for albumin and globulin were chosen to classify them into low or high groups. Their associations with all-cause and cardiovascular (CV) mortality were examined in Cox regression models adjusted for confounding clinical and laboratory data. Results: Patients, 52.91 ± 15.2 years old and 47.8% men, had a median (interquartile range) value of 3.3 (2.9−3.8) g/dL for albumin and 2.8 (2.5−3.2) g/dL for globulin, respectively. Patients with low albumin and high globulin had the highest all-cause mortality and CV mortality, with adjusted hazard ratios of 3.87 (95% CI 1.83−8.20, p < 0.001) and 5.65 (95% CI 2.23−14.34, p < 0.001), respectively, compared with those with a high albumin and low globulin having the lowest mortality rate. Sensitivity analyses further confirmed this relationship. Conclusions: A patient profile of either low albumin or high globulin is linked to a higher risk for mortality, particularly for a profile of both low albumin and high globulin compared with one without either of them. Further studies are needed to explore the mechanisms underlying this phenomenon and how to improve clinical outcomes in those high-risk patients.

Keywords: albumin; cardiovascular disease; chronic kidney disease; globulin; mortality; peritoneal dialysis (PD).

PubMed Disclaimer

Conflict of interest statement

There were no competing interests.

Figures

Figure 1
Figure 1
Kaplan–Meier curve of the overall patient survival, according to the groups stratified by albumin and globulin (log–rank test, p < 0.001).
Figure 2
Figure 2
Kaplan–Meier curve of cardiovascular survival according to the groups stratified by albumin and globulin (log–rank test, p < 0.001).

References

    1. Etgen T., Chonchol M., Förstl H., Sander D. Chronic kidney disease and cognitive impairment: A systematic review and meta-analysis. Am. J. Nephrol. 2012;35:474–482. doi: 10.1159/000338135. - DOI - PubMed
    1. Chin H.J., Song Y.R., Lee J.J., Lee S.B., Kim K.W., Na K.Y., Kim S., Chae D.W. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: A population-based study. Nephrol. Dial. Transplant. 2008;23:2810–2817. doi: 10.1093/ndt/gfn132. - DOI - PubMed
    1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351:1296–1305. doi: 10.1056/NEJMoa041031. - DOI - PubMed
    1. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., Hobbs F.D. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0158765. doi: 10.1371/journal.pone.0158765. - DOI - PMC - PubMed
    1. Liyanage T., Ninomiya T., Jha V., Neal B., Patrice H.M., Okpechi I., Zhao M.H., Lv J., Garg A.X., Knight J., et al. Worldwide access to treatment for end-stage kidney disease: A systematic review. Lancet. 2015;385:1975–1982. doi: 10.1016/S0140-6736(14)61601-9. - DOI - PubMed